Close Window
Aetna Aetna
Clinical Policy Bulletin:
Benign Prostatic Hypertrophy (BPH) Treatments
Number: 0079


Policy

  1. Aetna considers the following approaches to the treatment of benign prostate hypertrophy (BPH) medically necessary for members with benign prostatic hypertrophy as alternatives to transurethral resection of the prostate (TURP):

    1. Alpha adrenergic blockers (alfuzosin, doxazosin, silodosin, tamsulosin, and terazosin)
    2. Hormonal manipulation (including finasteride, dutasteride, and dutasteride plus tamsulosin)
    3. Interstitial laser coagulation of the prostate (ILCP)
    4. Laser prostatectomy
    5. Laser based procedures including contact laser ablation of the prostate (CLAP), holmium laser procedures of the prostate (HoLAP, HoLEP, HoLRP), photoselective laser vaporization of the prostate (PVP), transurethral ultrasound-guided laser induced prostatectomy (TULIP), and visually-guided laser ablation of the prostate (VLAP, also called non-contact laser ablation of the prostate)
    6. Prostatic urethral lift 
    7. Tadalafil (5 mg daily dose) (Note: Some plans exclude coverage of tadalafil; please check benefit plan descriptions)
    8. Transurethral electrovaporization of the prostate (TUVP)
    9. Transurethral incision of the prostate (TUIP)
    10. Transurethral microwave thermotherapy (TUMT)
    11. Transurethral needle ablation (TUNA), also known as transurethral radiofrequency needle ablation (RFNA)
    12. Ultrasonic aspiration.

    Laser prostatecctomy, ILCP, other laser based prostate procedures, prostatic urethral lift, TUVP, TUIP, TUMT, TUNA and ultrasonic aspiration of prostate are experimental and investigational for other indications. See also CPB 0100 - Cryoablation.

  2. Aetna considers the UroLume endourethral prosthesis (urethral stent) medically necessary to relieve prostatic obstruction secondary to BPH in men at least 60 years of age, or men under 60 years of age who are poor surgical candidates, and whose prostates are at least 2.5 cm in length.  (Note: UroLume is not intended for temporary use).

    UroLume endourethral prosthesis is also considered medically necessary for the treatment of recurrent bulbar urethral stenoses/strictures when previous therapeutic approaches such as dilation, urethrotomy or urethroplasty have failed (i.e., treatment was ineffective or there is recurrent stricture requiring additional treatment).

    Aetna considers the UroLume endourethral prosthesis experimental and investigational for other indications because its effectiveness for indications other than the ones listed above has not been established.

  3. Aetna considers the following approaches for the treatment of BPH to be experimental and investigational because the effectiveness of these interventions has not been established by the peer-reviewed medical literature:

    1. Absolute ethanol injection (transurethral)
    2. Botulinum toxin
    3. Cryosurgical ablation
    4. Endoscopic balloon dilation of the prostate
    5. Lutenizing hormone-releasing hormone antagonists
    6. Plasma kinetic vaporization (PlasmaKinetic Tissue Management System, Gyrus, Maple Grove, MN)
    7. Prostatic arterial embolization (transcatheter embolization)
    8. Temporary prostatic urethral stent
    9. Transrectal thermal therapy (including transrectal microwave hyperthermia, transrectal radiofrequency hyperthermia, transrectal electrothermal hyperthermia, and transrectal high-intensity focused ultrasound)
    10. Water-induced thermotherapy (also known as hot-water balloon thermoablation and thermourethral hot-water therapy).


Background

This policy is based primarily on the practice guideline of management of benign prostatic hyperplasia (BPH) from the American Urological Association.  While a number of treatment modalities have been shown to be effective for BPH, it is not yet evident which of these techniques will prove to be superior or which will approach the effectiveness of transurethral resection of the prostate (TURP) in treating BPH.

Temporary stents are designed primarily for short-term use in the treatment of symptomatic BPH, for a duration of 6 months to 3 years (van Dijk and de la Rosette, 2003).  Temporary stents are made of non-absorbable material, which prevents epithelial ingrowth and therefore allows easy removal.  However, this may lead to unintended migration.  Some temporary stents are biodegradable, so that they break down into small fragments, which are excreted through the urethra over time.  Although no explantation of biodegradable stents is required, the excreted fragments may cause urethral obstruction.

According to the guidelines by the American Urological Association (AUA, 2003), "because prostatic stents are associated with significant complications, such as encrustation, infection and chronic pain, their placement should be considered only in high-risk patients, especially those with urinary retention".  AUA guidelines explain: "Clinical trials of temporary prostatic stents are ongoing, and some long-term efficacy and safety studies have been published.  It is unclear whether prostatic stents have applications in men with symptomatic BPH who have not developed urinary retention and whose medical conditions permit other forms of treatment."

One temporary prostatic urethral stent currently in development is the Spanner, which is designed for temporary use (30 days or less) in men with bladder outlet obstruction to reduce elevated post-void residual and improve voiding symptoms.  The stent design is very similar to the proximal 4 to 6 cm portion of a Foley catheter.  It includes a proximal balloon to prevent distal displacement, a urine port situated cephalad to the balloon, and a reinforced stent of various lengths to span most of the prostatic urethra.  There is also a distal anchor mechanism attached by sutures, and a retrieval suture which extends to the meatus and deflates the proximal balloon when pulled.

Corica et al (2004) reported that the Spanner significantly improved voiding function and quality of life among patients with prostatic urethral obstruction (n = 30).  However, in a review on recent developments in the management of symptomatic BPH, Ogiste and colleagues (2003) stated that the role of stents as an intermediary in cases of treatment failure, or as definitive therapy for BPH and its associated problems are still unclear, when compared with newer, minimally invasive options.  Current literature on stents is relatively sparse.  However, recent studies showed that permanent and temporary prostatic urethral stenting are effective in relieving obstruction and urinary retention.  Nevertheless larger controlled clinical studies are needed to demonstrate the real value of this intervention.

Azuyma and Chancellor (2004) commented that although the results of the use of bioabsorbable spiral stents are encouraging, "there are still too many failures."  The authors state that controlled studies are needed to compare bioabsorbable stents with other forms of therapy.

The California Technology Assessment Forum (2002) concluded that water-induced thermotherapy for BPH does not meet CTAF's technology assessment criteria.  The assessment concluded that "[e]xisting studies have not yet demonstrated that WIT results in better health outcomes as much as or more than the established alternative of TURP, TUNA, or microwave thermotherapy."  Furthermore, in a review on minimally invasive therapies for BPH, Naspro et al (2005) noted that "currently, transurethral microwave thermotherapy seems to offer the soundest basis for management of the condition, providing the longest term follow up and the largest numbers of studies completed to date.  Among surgical alternatives, holmium laser enucleation has gained ground as an encouraging new approach, being similar to standard transurethral resection of the prostate, but reducing perioperative morbidity with the same long-term results.  More randomized comparisons correctly conducted need to be undertaken before an accurate general picture is available for the urologist".

Transurethral electrovaporization of the prostate (TUVP) is another alternative, minimally invasive procedures to treat BPH.  This procedure combines electrosurgical vaporization and desiccation to remove obstructive hyperplastic prostatic tissue with minimal morbidity.  It entails a special electrosurgical modification involving a grooved roller electrode with a large surface area and multiple edges of contact; thus allowing high current density to be delivered to an extensive area of tissue to be vaporized.  The device fits standard resectoscopic equipment, and its use requires no special skills other than those needed for conventional TURP.

Fowler et al (2005) compared the clinical and cost-effectiveness of TUVP with TURP.  Men requiring surgery for lower urinary tract symptoms deemed to be due to BPH were recruited from 4 centers in south-east England.  Main outcome measures were the International Prostate Symptom Score (IPSS) and the IPSS quality of life (QOL) question.  Secondary outcome measures included urinary flow rate, post-void urinary volume, prostate volume and pressure-flow urodynamics.  TURP and TUVP were both effective in producing a clinically important reduction in IPSS and positive change in the IPSS QOL question.  The success rate for relief of symptoms was 85 % for TURP and 74 % for TUVP.  Neither the success of the treatment nor the change in aggregated IPSS was significantly different between the groups.  The improvement was sustained to 24 months after treatment with no significant difference between the groups.  The effectiveness of both treatments was also equivalent when assessed through improvement in objective measures of urinary tract function, reduction in prostate size and the change in health questions of SF-36.  The absolute incidence of adverse events was similar between the 2 groups.  The incidence of severe or prolonged bleeding was less with TUVP, as evidenced by the need for blood transfusion and the drop in hemoglobin level 24 hours post-operatively.  This study did not show any significant difference in inpatient stay or use of outpatient resources between the groups.  The authors concluded that TURP and TUVP are equivalently effective in improving the symptoms of benign prostatic enlargement over at least 2 years.  TUVP is associated with less morbidity due to hemorrhage than TURP.  This finding is in agreement with that of the National Institute for Health and Clinical Excellence (2003), which stated that there is adequate support for the use of TUVP, and that of Nohuglu et al (2005) who found that TUVP is as effective as TURP with similar morbidity.  The advantages of TUVP are that the urethral catheter is withdrawn earlier, hospitalization is shorter, and bleeding is less.

Thomas et al (2006) noted that botulinum neurotoxin (BoNT) application recently has been extended to prostate disorders.  While BoNT has shown promising preliminary results for male lower urinary tract symptoms, and translational research suggests novel mechanism of action of BoNT in the prostate, it is important to remember that the application of BoNT in the prostate is not approved by the regulatory agencies and caution should be applied until larger randomized clinical trials are completed.  This is in agreement with the observations of Azzouzi et al (2006) as well as Chuang and Chancellor (2006).

Kuo and Liu (2009) evaluated the effectiveness of BoNT-A in patients with large BPH with an unsatisfactory response to combined alpha-blocker and 5-alpha-reductase inhibitor therapy.  A total of 60 patients with total prostate volume (TPV) of greater than 60 ml with unsatisfactory response to combination medical therapy were randomly assigned to receive add-on intra-prostatic BoNT-A injection (n = 30) or continued medical therapy (control group).  Patients in the treatment group received 200 to 600 U of Botox injected into the prostate.  Outcome parameters including IPSS, quality of life index (QOL-I), TPV, maximum flow rate (Q(max)) and post-void residual (PVR) volume were compared between treatment and control groups at baseline, 6 months and 12 months.  Significant decreases in IPSS, QOL-I and TPV, and increase in Q(max) were observed at 6 months and remained stable at 12 months in the treatment group.  Improvements in IPSS and QOL-I were also observed at 6 months and a decrease in TPV at 12 months was noted in the control group.  However, no significant changes in any parameters except for QOL-I at 6 and 12 months were noted between the treatment and control groups.  Acute urinary retention developed in 3 patients receiving BoNT-A treatment.  Three BoNT-A and 2 medical treatment patients converted to trans-urethral surgery at the end of study.  The authors concluded that the findings of this study showed that add-on prostatic BoNT-A medical treatment can reduce prostate volume and improve lower urinary tract symptom score and QOL-I within 6 months in the treatment of large BPH.  However, the therapeutic effect at 12 months was similar to combination medical treatment.

Oeconomou and Madersbacher (2010) summarized the mechanisms through which BoNT-A could inhibit the progression of BPH and eliminate the lower urinary tract symptoms (LUTS) according to the findings of animal studies.  Furthermore, these researchers reviewed clinical studies to report the safety and effectiveness of intra-prostatic BoNT-A injection according to various injection protocols.  The experimental studies reported induced relaxation of the prostate, atrophy, and reduction in its size through inhibition of the trophic effect of the autonomic system on the prostate gland.  Also, a possible mechanism of reduction in LUTS might take place through inhibition of sensory afferents from the prostate to the spinal cord.  Clinical studies reported symptomatic relief and improvement in the measured parameters during the follow-up period, whereas local or systematic side-effects are rare.  The authors concluded that it should be recognized that, at present, this therapy is still experimental.  Although the results of the clinical studies are encouraging, the level of evidence is low.  Large-scale, clinical, placebo-controlled, randomized studies, including long-term surveillance to document the evidence of this therapy are needed.

In a phase II prospective study, Richter et al (2009) recorded the effectiveness and complications of holmium laser enucleation of the prostate (HoLEP) in the first post-operative year.  Eighty-six of 343 consecutive patients with benign prostatic obstruction (IPSS greater than 10] were treated with the VersaPulse 100-W laser (Lumenis), 2.0 J/50 Hz or 3.2 J/25 Hz.  Pre-operative and post-operative prostate-specific antigen (PSA), Q(max), IPSS, prostate gland volume, and PVR volume were prospectively measured.  The median follow-up time was 8 months (3 to 21).  Median patient age was 71 (50 to 83) years, and mean operating time was 77.5 (9 to 135) mins.  There was only 1 case of significant bleeding.  In 14 of 86 cases (16 %), HoLEP was combined with TURP.  Short-term voiding complaints were expressed by 26.7 % of the questioned patients.  The length of hospital stay was in most cases less than 48 hrs.  IPSS, Q(max), PSA, PVR volume, gland volumes, and QOL improved significantly after 3 months, and all parameters remained unchanged after 12 months.  The re-operation rate within 12 months was 6.8 %.  The authors concluded that the advantage of HoLEP over TURP is the very low bleeding rate and thus a shorter hospital stay and possible out-patient therapy.  In particular, patients with prostate gland volume less than 50 mls profit from HoLEP.  Post-operative voiding complaints are comparable to those with TURP.  Moreover, the authors stated that long-term results are needed to confirm the low re-operation rate.

Erol et al (2009) prospectively evaluated vaporization efficiency of the high-power, 980-nm diode laser for bladder outlet obstruction due to BPH.  A total of 47 consecutive patients were included in the study.  Inclusion criteria were maximal flow rate 12 ml per second or less with voided volume 150 ml or greater, IPSS of 12 or greater, and QOL score 3 or greater.  Patients with a history of neurogenic voiding dysfunction, chronic prostatitis, or prostate or bladder cancer were excluded from analysis.  Pre-operative maximal flow rate, post-void residual urine, IPSS, QOL, International Index of Erectile Function-5, PSA, and prostate volume were compared with values at 3 and 6 months.  Complications were assessed.  Month 3 assessment revealed that the mean (+/- SD) IPSS decreased significantly from 21.93 +/- 4.88 to 10.31 +/- 3.79 (p = 0.0001).  The mean maximal flow rate increased significantly from 8.87 +/- 2.18 to 17.51 +/- 4.09 ml per second (p = 0.0001).  Quality of life score changed considerably compared to baseline.  All of these values showed slight improvement at month 6.  There was no deterioration in erectile function according to the International Index of Erectile Function-5 short form.  Post-void residual urine decreased significantly; reductions in prostate volume and PSA were also significant.  The most common post-operative complications were retrograde ejaculation (13 of 41 patients or 31.7 %) and irritative symptoms (11 of 47 or 23.4 %), which subsided in the maximal flow rate at 2 weeks.  Re-catheterization was necessary in 2 patients due to urinary retention after catheter removal; 2 patients had temporary combined urge and stress incontinence for 2 weeks.  Late bleeding in 1 patient 4 weeks post-operatively resulted in catheterization and irrigation.  The authors concluded that the high-power diode laser provided significant improvements in IPSS and the maximal flow rate with low morbidity.  Thus, these results of prostate vaporization with the high-power diode laser, representing what is to the authors' knowledge the first clinical study in the literature, are encouraging.  The authors stated that further randomized clinical trials are needed to ascertain the role of high-power diode laser as an alternative to TURP or other laser techniques for BPH.

Van Cleynenbreugel et al (2009) presented recent clinical and urodynamic data on trans-urethral photo-selective vaporization of the prostate, and reported on the recent introduction of the 120-W GreenLight laser (GLL) high-performance system.  These researchers noted that recent studies confirm improved urodynamic findings following GLL treatment.  Moreover, it can be used safely in high-risk patients (e.g., those on anti-coagulant medication and patients with cardiopulmonary diseases), and has been proposed as an alternative to prostate enucleation for larger glands.  The introduction of the 120-W high-performance system GLL does, however, place distinct demands on training and operative schemes.  The authors concluded that the clinical results of GreenLight prostate vaporization are equivalent to those following TURP, with reduced operative risks, even for the high-risk patient.  These clinical benefits have been confirmed by improved urodynamic parameters.  Moreover, they noted that the potential advantages of the new 120-W high-performance system GLL have yet to be validated in larger randomized trials.

Ruszat et al (2008) evaluated the intermediate-term clinical effectiveness and the rate of complications in 80-W photo-selective vaporization of the prostate (PVP) with the potassium-titanyl-phosphate laser (GreenLight, Minnetonka, MN) compared with TURP in a prospective non-randomized 2-center study.  A total of 396 patients (PVP = 269, TURP = 127) with lower urinary tract symptoms secondary to BPH were included in the study.  There was a significant difference in mean age (72 years for PVP versus 68 for TURP, p = 0.001).  Patients were therefore stratified in age categories (less than 70, 70 to 80, greater than 80 years) and compared for peri-operative variables, functional outcome and complications, with a follow-up of up to 24 months.  The mean prostate size was greater (overall, 62 versus 48 mls, p < 0.001) and mean operative duration longer (overall 72 versus 53 mins; p = 0.001) for PVP in all age categories.  The rate of intra-operative bleeding (3 % versus 11 %), blood transfusions (0 % versus 5.5 %) and capsule perforations (0.4 % versus 6.3 %), and early post-operative clot retention (0.4 % versus 3.9 %) was significantly lower for PVP.  Hospitalization time was significantly shorter in the PVP group for patients aged less than 70 years (3.0 versus 4.7 days) and 70 to 80 years (4.0 versus 5.0 days; p = 0.001).  The improvement of peak urinary flow rate was higher after TURP for any age category.  The IPSS and PVR volume during the follow-up showed no significant difference.  After 12 months, the overall prostate size reduction was 63 % (-30 mls) after TURP and 44 % (-27 mls) after PVP.  The rate of repeat TURP/PVP was higher in the PVP group (6.7 % versus 3.9 %, not significant) within the follow-up of up to 2 years.  The incidence of urethral and bladder neck strictures was comparable.  The authors concluded that PVP was more favorable in terms of peri-operative safety.  Although patients assigned for PVP were older and had larger prostates, PVP resulted in a similar functional outcome.  They stated that further follow-up is needed to draw final conclusions about the long-term effectiveness of PVP.

Naspro and colleagues (2009) noted that HoLEP and 532-nm laser vaporization of the prostate (with potassium titanyl phosphate [KTP] or lithium borate [LBO]) are promising alternatives to TURP and open prostatectomy (OP).  These investigators evaluated the safety, effectiveness, and durability by analyzing the most recent evidence of both techniques, aiming to identify advantages, pitfalls, and unresolved issues.  A Medline search of recently published data (2006 to 2008) regarding both techniques over the last 2 years (January 2006 to September 2008) was performed using evidence obtained from randomized trials (level of evidence: 1b), well-designed controlled studies without randomization (level of evidence: 2a), individual cohort studies (level of evidence: 2b), individual case control studies (level of evidence: 3), and case series (level of evidence: 4).  In the last 2 years, several case-control and cohort studies have demonstrated reproducibility, safety, and effectiveness of HoLEP and 80-W KTP laser vaporization.  Four randomized controlled trials (RCTs) were available for HoLEP, 2 compared with TURP and 2 compared with OP, with follow-up greater than 24 months.  Results confirmed general effectiveness and durability of HoLEP, as compared with both standard techniques.  Only 2 RCTs were available comparing KTP laser vaporization with TURP with short-term follow-up, and only 1 RCT was available comparing KTP laser vaporization with OP.  The results confirmed the overall low peri-operative morbidity of KTP laser vaporization, although effectiveness was comparable to TURP in the short-term, despite a higher re-operation rate.  The authors concluded that although they are at different points of maturation, KTP or LBO laser vaporization and HoLEP are promising alternatives to both TURP and OP; KTP laser vaporization needs further evaluation to define the re-operation rate.  Increasing the number of quality prospective RCTs with adequate follow-up is mandatory to tailor each technique to the right patient.

Chung and Te (2009) stated that traditionally, the gold standard for treatment of BPH has been the electrocautery-based TURP.  However, the number of laser techniques being performed is rapidly increasing.  Potential advantages of laser therapy over traditional TURP include decreased morbidity and shorter hospital stay.  There are several techniques for laser prostatectomy that continue to evolve.  The main competing techniques are currently the HoLEP and the 80-W 532-nm laser prostatectomy.  The HoLEP, using the Holmium:YAG laser, has been shown to have clinical results similar to TURP and is suitable for patients on anti-coagulation as well as those with large prostates.  Disadvantages of this technique are the high learning curve and requirement of a morcellator.  When used to treat BPH, studies have demonstrated that, like the HoLEP, the 80-W KTP laser is safe and effective in patients with large prostates and in those taking oral anti-coagulation.  Several studies have compared these 2 techniques to TURP.  Frequently reported advantages of the HoLEP over the 80-W laser prostatectomy are the availability after the procedure of a pathology specimen and ability to remove a higher percentage of prostate tissue during resection.  However, the trans-urethral laser enucleation of the prostate addresses these concerns and has shown to have durable outcomes at 2-year follow-up.  Two new laser systems and techniques, the thulium laser and the 980-nm laser, have emerged recently.  However, clinical data from these procedures are in their infancy and large long-term studies are needed to ascertain their clinical effectiveness.

Lourenco and colleagues (2008) ascertained the clinical effectiveness and cost utility of procedures alternative to TURP for BPH unresponsive to expectant, non-surgical treatments.  Electronic searches of 13 databases to identify relevant RCTs were carried out.  Two reviewers independently assessed study quality and extracted data.  The International Prostate Symptom Score/American Urological Association (IPSS/AUA) symptom score was the primary outcome; others included QOL, peak urine flow rate and adverse effects.  Cost-effectiveness was assessed using a Markov model reflecting likely care pathways.  A total of 156 reports describing 88 RCTs were included.  Most had fewer than 100 participants (range of 12 to 234).  It was found that TURP provided consistent, high-level, long-term symptomatic improvement.  Minimally invasive procedures resulted in less marked improvement.  Ablative procedures gave improvements equivalent to TURP.  Furthermore, HoLEP resulted in greater improvement in flow rate.  Holmium laser enucleation of the prostate is unique amongst the newer technologies in offering an advantage in urodynamic outcomes over TURP, although long-term follow-up data are lacking.  Severe blood loss was more common following TURP.  Rates of incontinence were similar across all interventions other than TUNA and laser coagulation, for which lower rates were reported.  Acute retention and re-operation were commoner with newer technologies, especially minimally invasive interventions.  The economic model suggested that minimally invasive procedures were unlikely to be cost-effective compared with TURP.  Transurethral vaporization of the prostate was both less costly and less effective than TURP; whereas HoLEP was estimated to be more cost-effective than a single TURP but less effective than a strategy involving repeat TURP, if necessary.  The base-case analysis suggested an 80 % chance that TUVP, followed by HoLEP if required, would be cost-effective at a threshold of 20,000 pounds per quality-adjusted life-year.  At a 50,000 pounds threshold, TUVP, followed by TURP as required, would be cost-effective, although considerable uncertainty surrounds this finding.  The main limitations are the quantity and quality of the data available, in the context of multiple comparisons.   The authors concluded that in the absence of strong evidence in favor of newer methods, the standard -- TURP -- remains both clinically effective and cost-effective.  There is a need for further research to establish (i) how many years of medical treatment are necessary to offset the cost of treatment with a minimally invasive or ablative intervention; (ii) more cost-effective alternatives to TURP; and (iii) strategies to improve outcomes after TURP.

Hashim and Abrams (2010) noted that benign prostatic enlargement (BPE) leading to benign prostatic obstruction (BPO) affects an increasing number of men as they grow older.  They can affect QOL and cause LUTS including urinary retention.  The currently available pharmacotherapies are alpha-blockers and 5-alpha reductase inhibitors, which may be effective but can have adverse effects and long-term compliance problems.  Thus, it is important to find new medical treatments for LUTS/BPO and this review aimed to identify the potential future drugs undergoing clinical trials in this field.  Articles were identified by means of a computerized Google, PubMed and Cochrane Library search over the last 10 years (using the following keywords: benign prostate hyperplasia, enlargement and obstruction) and a search of the PharmaProjects database.  The exact etiology of BPH and its consequences, BPE and BPO, are not known; however, aging and functioning testes have been implicated.  Several classes of drugs are currently undergoing clinical trials such as phosphodiesterase-5 (PDE5) inhibitors and lutenizing hormone-releasing hormone antagonists.  Others include phytoestrogens, progestogens, NX1207 and PRX302.  Some of these work by affecting testosterone level and, therefore, on the static component of BPO, while it is not known how the rest work.  The authors stated that until the exact etiology of BPH/BPE/BPO is known, it is unlikely the cure for this disorder will be found.

Wang (2010) examined the use of PDE5 inhibitors for BPH/LUTS treatment and highlighted the clinical significance.  Pre-clinical and clinical studies have provided promising evidence that PDE5 inhibitors may be an effective and well-tolerated treatment option for BPH/LUTS.  Combination therapy using PDE5 inhibitors and alpha1-adrenergic blockers resulted in greater improvements in BPH/LUTS than did either drug alone.  There has been increasing interest in the use of PDE5 inhibitors to treat BPH/LUTS.  Combination of PDE5 inhibitors and alpha1-adrenergic blockers may have an additive beneficial effect on BPH/LUTS compared with monotherapy.  Mechanisms of action of nitric oxide/cyclic guanosine monophosphate/PDE5 pathway in the treatment of BPH/LUTS deserve further investigations.  The author concluded that larger-scale, well-designed clinical trials are needed to ascertain the safety, effectiveness and cost-effectiveness of PDE5 inhibitors in the treatment of LUTS secondary to BPH.

Andersson et al (2011) reviewed the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by PDE5 inhibition.  Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files.  Articles were selected for review based on describing in-vitro, pre-clinical, or clinical studies of pathological processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract.  Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic over-activity; increased bladder afferent activity; and pelvic ischemia.  Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men.  The authors concluded that the pathophysiology of male LUTS is complex and not completely understood.  LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap.  While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS.

On October 6, 2011, the FDA approved tadalafil (Cialis) for the treatmentof of BPH, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously.  Tadalafil should not be used in patients taking nitrates (e.g., nitroglycerin) because the combination can cause an unsafe decrease in blood pressure.   Also, the use of tadalafil in combination with alpha blockers for the treatment of BPH is not recommended because the combination has not been adequately studied for the treatment of BPH, and there is a risk of lowering blood pressure.  In 2 clinical trials, men with BPH who took 5 mg of tadalafil once-daily experienced a statistically significant improvement in their symptoms of BPH compared to men who were treated with placebo.  The trials based their findings on a reduction in total IPSS scores.  In a 3rd study, men who experienced both erectile dysfunction (ED) and BPH and who took 5 mg of tadalafil once-daily had improvement in both their symptoms of BPH and in their ED compared to men who were treated with placebo.  The improvement in ED was measured using the Erectile Function domain score of the International Index of Erectile Function.

While surgical resection and ablation using many different forms of energy remain the reference standard for BPH treatment, many patients seek a less invasive approach that will improve symptoms but not risk the complications associated with tissue removal.  The UroLift system (NeoTract Inc., Pleasanton, CA) permanent implant is such a modality; it is delivered under cystoscopic visualization.  The implant "holds open" the lateral prostatic lobes creating a passage through the obstructed prostatic urethra.  Voiding and symptoms are significantly improved without the morbidity or possible complications following prostate resection.  The entire procedure can be readily performed using local anesthesia (Barkin et al, 2012).

On September 13, 2013, the FDA approved the marketing of the UroLift, the first permanent implant to relieve low or blocked urine flow in men aged 50 and older with BPH.  Minor adverse events reported included pain or burning during urination, blood in the urine, frequent or urgent need to urinate, incomplete emptying of the bladder, and decreased urine flow.

Chin et al (2012) evaluated the effectiveness of the prostatic urethral lift in relieving LUTS secondary to BPH.  A total of 64 men, aged greater than or equal to 55 years, with moderate-to-severe symptomatic BPH were treated and followed-up at 6 Australian institutions.  The treatment consisted of transurethral delivery of small implants to secure the prostatic lobes in an open condition, thereby reducing obstruction of the urethral lumen.  The effectiveness, including International Prostate Symptom Score, quality of life, benign prostatic hyperplasia Impact Index, and peak urethral flow rate were assessed at 2 weeks and 3, 6, 12, and 24 months.  The effect of this treatment on erectile and ejaculatory function was assessed using the Sexual Health Inventory for Men and Male Sexual Health Questionnaire for Ejaculatory Dysfunction.  The prostatic urethral lift improved LUTS symptoms rapidly and durably.  The International Prostate Symptom Score was reduced 42 % at 2 weeks, 49 % at 6 months, and 42 % at 2 years in evaluable patients.  The peak flow rate improved by greater than or equal to 30 % (2.4 ml/s) at all intervals compared with baseline.  No compromise in sexual function was observed after this treatment.  The authors concluded that the findings of the present study demonstrated that LUTS and flow improvements without compromising sexual function.  Moreover, they stated that although this was an early study with a small cohort, this therapy showed promise as a new option for patients with LUTS.

Roehrborn et al (2013) reported the first multi-center randomized blinded trial of the prostatic urethral lift for the treatment of LUTS secondary to BPH.  Men at least 50 years old with AUASI (American Urological Association Symptom Index) 13 or greater, a maximum flow rate 12 ml/s or less and a prostate 30 to 80 cc were randomized 2:1 between prostatic urethral lift and sham.  In the prostatic urethral lift group, small permanent implants are placed within the prostate to retract encroaching lobes and open the prostatic urethra.  Sham entailed rigid cystoscopy with sounds mimicking the prostatic urethral lift.  The primary end-point was comparison of AUASI reduction at 3 months.  The prostatic urethral lift arm subjects were followed to 1 year and assessed for LUTS, peak urinary flow rate, quality of life and sexual function.  A total of 206 men were randomized (prostatic urethral lift 140 versus sham 66).  The prostatic urethral lift and sham AUASI was reduced by 11.1 ± 7.67 and 5.9 ± 7.66, respectively (p = 0.003), thus meeting the primary end-point.  Prostatic urethral lift subjects experienced AUASI reduction from 22.1 baseline to 18.0, 11.0 and 11.1 at 2 weeks, 3 months and 12 months, respectively, p < 0.001.  Peak urinary flow rate increased 4.4 ml/s at 3 months and was sustained at 4.0 ml/s at 12 months, p < 0.001.  Adverse events were typically mild and transient.  There was no occurrence of de-novo ejaculatory or erectile dysfunction.  The authors concluded that the prostatic urethral lift, inserted with the patient under local anesthesia, provided rapid and sustained improvement in symptoms and flow, while preserving sexual function.

McNicholas et al (2013) described the surgical technique and results of a novel minimally invasive implant procedure that offers symptom relief and improved voiding flow in an international series of patients.  A total of 102 men with symptomatic BPH were consecutively treated at 7 centers across 5 countries.  Patients were evaluated up to a median follow-up of 1 year post-procedure.  Average age, prostate size, and IPSS were 68 years, 48 cm(3), and 23, respectively.  The prostatic urethral lift mechanically opens the prostatic urethra with UroLift implants that were placed transurethrally under cystoscopic visualization, thereby separating the encroaching prostatic lobes.  Patients were evaluated pre- and post-operatively by the IPSS, QOL scale, Benign Prostatic Hyperplasia Impact Index, maximum flow rate (Qmax), and adverse event reports including sexual function.  All procedures were completed successfully with a mean of 4.5 implants without serious adverse effects.  Patients experienced symptom relief by 2 weeks that was sustained to 12 months.  Mean IPSS, QOL, and Qmax improved 36 %, 39 %, and 38 % by 2 weeks, and 52 %, 53 %, and 51 % at 12 months (p < 0.001), respectively.  Adverse events were mild and transient.  There were no reports of loss of antegrade ejaculation.  A total of 6.5% of patients progressed to TURP without complication.  The authors concluded that prostatic urethral lift has promise for BPH.  It is minimally invasive, can be done under local anesthesia, does not appear to cause retrograde ejaculation, and improves symptoms and voiding flow.

McVary et al (2014) analyzed data obtained from a randomized controlled blinded study of the prostatic urethral lift (PUL) to evaluate the sexual side effects of this novel treatment.  Men greater than or equal to 50 years with prostates 30 to 80 cc, IPSS greater than 12, and Qmax less than or equal to 12 ml/s were randomized 2:1 between PUL and sham.  Sexual activity was not an inclusion criterion.  In PUL, permanent trans-prostatic implants were placed to retract encroaching lateral lobes and open the prostatic fossa.  Sham entailed rigid cystoscopy with sounds to mimic PUL and a blinding screen.  Blinded groups were compared at 3 months and active-arm then followed to 12 months for LUTS with IPSS and for sexual function with sexual health inventory for men (SHIM) and Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD).  Subjects were censored from primary sexual function analysis if they had baseline SHIM less than 5 at enrollment.  Secondary stratified analysis by ED severity was conducted.  There was no evidence of degradation in erectile or ejaculatory function after PUL.  SHIM and MSHQ-EjD scores were not different from control at 3 months but were modestly improved and statistically different from baseline at 1 year.  Ejaculatory bother score was most improved with a 40 % improvement over baseline.  Twelve-month SHIM was significantly improved from baseline for men entering the study with severe ED (p = 0.016).  IPSS and Qmax were significantly superior to both control at 3 months and baseline at 1 year.  There was no instance of de-novo sustained anejaculation or ED over the course of the study.  The authors concluded that the PUL improved LUTS and urinary flow while preserving erectile and ejaculatory function.

Guidance from the National Institute for Health and Clinical Excellence (NICE, 2014) states: "Current evidence on the efficacy and safety of insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia is adequate to support the use of this procedure provided that normal arrangements are in place for clinical governance, consent and audit."

Fernandes et al (2012) stated that PAE gained special attention in the past years as a potential minimally invasive technique for BPH.  Treatment decisions are based on morbidity and quality-of-life issues and the patient has a central role in decision-making.  Medical therapy is a first-line treatment option and surgery is usually performed to improve symptoms and decrease the progression of disease in patients who develop complications or who have inadequately controlled symptoms on medical treatment.  The use of validated questionnaires to assess disease severity and sexual function, uroflowmetry studies, prostate-specific antigen and prostate volume measurements are essential when evaluating patients before PAE and to evaluate response to treatment.  The authors stated that PAE may be performed safely with minimal morbidity and without associated mortality.  The minimally invasive nature of the technique inducing a significant improvement in symptom severity associated with prostate volume reduction and a slight improvement in the sexual function are major advantages.  However, as with other surgical therapies for BPH, up to 15 % of patients fail to show improvement significantly after PAE, and there is a modest improvement of the peak urinary flow.

Pisco et al (2011) evaluated whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH).  A total of 15 patients (age range of 62 to 82 years; mean age of 74.1 years) with symptomatic BPH after failure of medical treatment were selected for PAE with non-spherical 200-μm polyvinyl alcohol particles.  The procedure was performed by a single femoral approach.  Technical success was considered when selective prostatic arterial catheterization and embolization was achieved on at least one pelvic side.  PAE was technically successful in 14 of the 15 patients (93.3 %).  There was a mean follow-up of 7.9 months (range of 3 to 12 months). International Prostate Symptom Score decreased a mean of 6.5 points (p = 0.005), quality of life improved 1.14 points (p = 0.065), International Index of Erectile Function increased 1.7 points (p = 0.063), and peak urinary flow increased 3.85 mL/sec (p = 0.015).  There was a mean prostate-specific antigen reduction of 2.27 ng/ml (p = 0.072) and a mean prostate volume decrease of 26.5 mL (p = 0.0001) by ultrasound and 28.9 mL (p = 0.008) by magnetic resonance imaging.  There was 1 major complication (a 1.5-cm(2) ischemic area of the bladder wall) and four clinical failures (28.6 %).  The authors concluded that in this small group of patients, PAE was a feasible procedure, with preliminary results and short-term follow-up suggesting good symptom control without sexual dysfunction in suitable candidates, associated with a reduction in prostate volume.

Pisco et al (2013) evaluated the safety, morbidity, and short- and intermediate-term results of PAE for BPH after failure of medical treatment.  Men older than 50 years with a diagnosis of BPH and moderate-to-severe lower urinary tract symptoms that were refractory to medical treatment for 6 months were eligible.  PAE with non-spherical 80-180-μm (mean of 100-μm) and 180-300-μm (mean of 200-μm) polyvinyl alcohol particles was performed by means of a single femoral approach in most cases.  Effectiveness variables of International Prostate Symptom Score (IPSS), quality of life (QOL) score, peak urinary flow, post-void residual volume, International Index Erectile Function (IIEF) score, prostate volume, and prostate-specific antigen level were assessed for up to 24 months after the procedure.  Statistical analysis included the Kaplan-Meier method and random-effects generalized least squares regression with autoregressive disturbance.  A total of 89 consecutive patients (mean age of 74.1 years) were included.  PAE was technically successful in 86 of the 89 patients (97 %).  Cumulative rates of clinical improvement in these patients were 78 % in the 54 patients evaluated at 6 months and 76 % in the 29 patients evaluated at 12 months.  At 1-month follow-up, IPSS decreased by 10 points, QOL score decreased by 2 points, peak urinary flow increased by 38 %, prostate volume decreased by 20 %, post-void residual volume decreased by 30 ml, and IIEF score increased by 0.5 point (all differences were significant at p < 0.01).  These changes were sustained throughout the observation period.  There was one major complication: Intraluminal necrotic tissue attached to the bladder, which was removed with simple surgery and did not necessitate wall reconstruction.  The authors concluded that PAE is a safe and effective procedure, with low morbidity, no sexual dysfunction, and good short- and intermediate-term symptomatic control associated with prostate volume reduction.

The 3 afore-mentioned studies appear to have been carried out by the same group of investigators.  These short- and intermediate-term findings need to be validated by well-designed studies. 

 
CPT Codes / HCPCS / ICD-9 Codes
CPT codes covered if selection criteria are met:
52282
52450
52601
52647
52648
52649
53850
53852
Prostatic urethral lift:
CPT codes not covered for indications listed in the CPB:
37242
53855
55873
75894
Other CPT codes related to the CPB:
52281
53000 - 53010
53600 - 53621
HCPCS codes covered is selection criteria are met:
C9739 Cystourethroscpy, with insertion of transprostatic implant;1l to 3 implants
C97740     4 or more implants
HCPCS codes not covered for indications listed in the CPB:
J1950 Injection, leuprolide acetate (for depot suspension), per 3.75 mg
J9155 Injection, Degarelix, 1 mg
J9202 Goserelin acetate implant, per 3.6 mg
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J9218 Leuprolide acetate, per 1 mg
J9219 Leuprolide acetate implant, 65 mg
J9226 Histrelin implant (Supprelin LA), 50 mg
J3315 Injection, triptorelin pamoate, 3.75 mg
S0090 Sildenafil citrate, 25 mg
ICD-9 codes covered if selection criteria are met:
598.00 - 598.9 Urethral stricture
600.00 - 600.01 Hypertrophy (benign) of prostate
600.10 - 600.11 Nodular prostate
600.20 - 600.21 Benign localized hyperplasia of prostate
600.90 - 600.91 Hyperplasia of prostate, unspecified
Other ICD-9 codes related to the CPB:
596.0 Bladder neck obstruction
596.8 Other specified disorders of bladder
599.6 Urinary obstruction, unspecified
788.20 - 788.29 Retention of urine


The above policy is based on the following references:
  1. UK National Health Service, Centre for Reviews and Dissemination. Benign prostatic hyperplasia. Effective Health Care Bull. 1995;2(2). Available at: http://www.york.ac.uk/inst/crd/ehc22.htm. Accessed July 13, 2001.
  2. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology. 1998;51(4A Suppl):23-31.
  3. Bruskewitz R, Issa MM, Roehrborn CG, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1998;159(5):1588-1593.
  4. Rosario DJ, Woo H, Potts KL, et al. Safety and efficacy of transurethral needle ablation of the prostate for symptomatic outlet obstruction. Br J Urol. 1997;80(4):579-586.
  5. Steele GS, Sleep DJ. Transurethral needle ablation of the prostate: A urodynamic based study with 2-year follow-up. J Urol. 1997;158(5):1834-1838.
  6. Naslund MJ. Transurethral needle ablation of the prostate. Urology. 1997;50(2):167-172.
  7. Ramon J, Lynch TH, Eardley I, et al. Transurethral needle ablation of the prostate for the treatment of benign prostate hyperplasia: A collaborative multicentre study. Br J Urol. 1997;80(1):128-134.
  8. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign Prostatic Hyperplasia: Diagnosis and Treatment. Clinical Practice Guideline No. 8. AHCPR Publication No. 94-0582. Rockville, MD: Agency for Health Care Policy and Research (AHCPR); February 1994. Available at: http://www.ahcpr.gov/clinic/cpgarchv.htm. Accessed July 13, 2001.
  9. Blute ML, Tomera KM, Hellerstein DK, et al. Transurethral microwave thermotherapy for management of benign prostatic hyperplasia. Results of the United States Prostatron cooperative study. J Urol. 1993;150(5 Pt 2):1591-1596.
  10. Bdesha AS, Bunce CJ, Kelleher JP, et al. Transurethral microwave treatment for benign prostatic hypertrophy. A randomized controlled trial. BMJ. 1993;306(6888):1293-1296.
  11. de la Rosette JJ, de Wildt MJ, Alivizatos G, et al. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: Placebo versus TUMT. Urology. 1994;44(1):58-63.
  12. Ogden CW, Reddy P, Johnson H, et al. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet. 1993;341(8836):14-17.
  13. Goldfarb B, Bartkiw T, Trachtenberg J. Microwave therapy of benign prostatic hyperplasia. Urol Clinics North Am. 1995;22(2):431-439.
  14. Djavan B, Madersbacher S, Klingler HC, et al. Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia. Tech Urol. 1999;5(1):12-20.
  15. Ramsey EW. Office treatment of benign prostatic hyperplasia. Urol Clin North Am. 1998;25(4):571-580.
  16. Lynch JH, Hofner K. Transurethral microwave thermotherapy. Eur Urol. 1999;35(2):129-137.
  17. Chapple CR, Issa MM, Woo H. Transurethral needle ablation (TUNA). A critical review of radiofrequency thermal therapy in the management of benign prostatic hyperplasia. Eur Urol. 1999;35(2):119-128.
  18. Djavan G, Larson TR, Blute ML, et al. Transurethral microwave thermotherapy: What role should it play versus medical management in the treatment of benign prostatic hyperplasia. Urology. 1998;52(6):935-947.
  19. Beduschi MC, Oesterling JE. Transurethral needle ablation of the prostate: A minimally invasive treatment for symptomatic benign prostatic hyperplasia. Mayo Clin Proc. 1998;73(7):696-701.
  20. Te AE, Kaplan SA. Transurethral electrovaporization of the prostate. Mayo Clin Proc. 1998;73(7):691-695.
  21. Blute ML, Larson TR, Hanson KA, et al. Current status of transurethral thermotherapy at the Mayo Clinic. Mayo Clin Proc. 1998;73(6):597-602.
  22. Kaplan SA. Minimally invasive alternative therapeutic options for lower urinary tract symptoms. Urology. 1998;51(4A Suppl):32-37.
  23. Jepsen JV, Bruskewitz RC. Recent developments in the surgical management of benign prostatic hyperplasia. Urology. 1998;51(4A Suppl):23-31.
  24. Stein BS. Neodymium:yttrium-aluminum-garnet laser prostatectomy. Mayo Clin Proc. 1998;73(8):787-791.
  25. Kabalin JN, Gilling PJ, Fraundorfer MR. Holmium:yttrium-aluminum-garnet laser prostatectomy. Mayo Clin Proc. 1998;73(8):792-797.
  26. Montorsi F, Guazzoni G, Rigatti P, et al. Is there a role for transrectal microwave hyperthermia in the treatment of benign prostatic hyperplasia? A critical review of a six-year experience. J Endourol. 1995;9(4):333-337.
  27. Culkin DJ, Anderson BW. Benign prostatic hyperplasia. In: Conn's Current Therapy. RE Rakel, ed. Philadelphia, PA: W.B. Saunders Co.; 1999:706-710.
  28. Presti JC Jr., et al. Urology. In: Current Medical Diagnosis & Treatment. 38th Ed. LM Tierney, Jr et al., eds. Stamford, CT. Appleton & Lange; 1999; Ch. 23:894-931.
  29. Frymann R, Cranston D, O'Boyle P. A review of studies published during 1998 examining the treatment and management of benign prostatic obstruction. BJU Int. 2000;85 (Suppl 1):46-53.
  30. Donatucci CF. Alternative methods for management of prostatic outflow obstruction. Curr Opin Urol. 1999;9(1):39-44.
  31. Lane T, Shah J. Clinical features and management of benign prostatic hyperplasia. Hosp Med. 1999;60(10):705-709.
  32. Eliasson T, Wagrell L. New technologies for the surgical management of symptomatic benign prostatic enlargement: Tolerability and morbidity of high energy transurethral microwave thermotherapy. Curr Opin Urol. 2000;10(1):15-17.
  33. Laguna P, Alivizatos G. Prostate specific antigen and benign prostatic hyperplasia. Curr Opin Urol. 2000;10(1):3-8.
  34. Corica FA, Cheng L, Ramnani D, et al. Transurethral hot-water balloon thermoablation for benign prostatic hyperplasia: Patient tolerance and pathologic findings. Urology. 2000;56(1):76-81.
  35. Badlani GH, Press SM, Defalco A, et al. Urolume endourethral prosthesis for the treatment of urethral stricture disease: Long-term results of the North American Multicenter UroLume Trial. Urology. 1995;45(5):846-856.
  36. Milroy E, Allen A. Long-term results of urolume urethral stent for recurrent urethral strictures. J Urol. 1996;155(3):904-908.
  37. Badlani GH. Role of permanent stents. J Endourol. 1997;11(6):473-475.
  38. Anjum MI, Chari R, Shetty A, et al. Long-term clinical results and quality of life after insertion of a self-expanding flexible endourethral prosthesis. Br J Urol. 1997;80(6):885-888.
  39. Sertcelik N, Sagnak L, Imamoglu A, et al. The use of self-expanding metallic urethral stents in the treatment of recurrent bulbar urethral strictures: Long-term results. BJU Int. 2000;86(6):686-689.
  40. Konety BR, Phelan MW, O'Donnell WF, et al. Urolume stent placement for the treatment of postbrachytherapy bladder outlet obstruction. Urology. 2000;55(5):721-724.
  41. Kapoor R, Liatsikos EN, Badlani G. Endoprostatic stents for management of benign prostatic hyperplasia. Curr Opin Urol. 2000;10(1):19-22.
  42. Goldberg SN, Hahn PF, McGovern FJ, et al. Benign prostatic hyperplasia: US-guided transrectal urethral enlargement with radiofrequency--initial results in a canine model. Radiology. 1998;208(2):491-498.
  43. Nakamura K, Baba S, Fukazawa R, et al. Treatment of benign prostatic hyperplasia with high intensity focused ultrasound: An initial clinical trial in Japan with magnetic resonance imaging of the treated area. Int J Urol. 1995;2(3):176-180.
  44. Bhanot SM, Grigor KM, Hargreave TB, et al. A radiofrequency method of thermal tissue ablation for benign prostatic hyperplasia. Urology. 1995;45(3):427-434.
  45. Madersbacher S, Susani M, Marberger M. Thermal ablation of BPH with transrectal high-intensity focused ultrasound. Prog Clin Biol Res. 1994;386:473-478.
  46. Kaplan SA, Shabsigh R, Soldo KA, et al. Transrectal hyperthermia in the management of men with prostatism: An algorithm for therapy. Br J Urol. 1993;72(2):195-200.
  47. Petrovich Z, Ameye F, Baert L, et al. New trends in the treatment of benign prostatic hyperplasia and carcinoma of the prostate. Am J Clin Oncol. 1993;16(3):187-200.
  48. Schulman CC, Vanden Bossche M. Hyperthermia and thermotherapy of benign prostatic hyperplasia: A critical review. Eur Urol. 1993;23 Suppl 1:53-59.
  49. Kaplan SA, Shabsigh R, Soldo KA, et al. Prostatic and periprostatic interstitial temperature measurements in patients treated with transrectal thermal therapy (local intracavitary microwave hyperthermia). J Urol. 1992;147(6):1562-1565.
  50. Institute for Clinical Systems Improvement (ICSI). Microwave thermotherapy for benign prostatic hypertrophy. Technology Assessment Report No. 42. Bloomington, MN: ICSI; February 1998.
  51. Cioanta I, Muschter R. Water-induced thermotherapy for benign prostatic hyperplasia. Tech Urol.  2000;6(4):294-299.
  52. Muschter R, Schorsch I, Danielli L, et al. Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: A prospective multicenter clinical trial. J Urol. 2000;164(5):1565-1569.
  53. Larson TR. Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology. 2002;59(2 Suppl 1):12-16.
  54. Zlotta AR, Djavan B. Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: Long-term data. Curr Opin Urol. 2002;12(1):7-14.
  55. Djavan B, Seitz C, Marberger M. Heat versus drugs in the treatment of benign prostatic hyperplasia. BJU Int. 2003;91(2):131-137.
  56. Hoffman RM, MacDonald R, Slaton JW, Wilt TJ. Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: A systematic review. J Urol. 2003;169(1):210-215.
  57. Swedish Council on Technology Assessment in Health Care (SBU). TUNA - Transurethral needle ablation for BPH - early assessment briefs (Alert). Stockholm, Sweden: SBU; 2002.
  58. Ditrolio J, Patel P, Watson RA, Irwin RJ. Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol. 2002;167(5):2100-2103; discussion 2103-2104.
  59. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Treatments for benign prostatic hypertrophy. Pre-assessment No. 17. Ottawa, ON: CCOHTA; 2003.
  60. Plante MK, Bunnell ML, Trotter SJ, et al. Transurethral prostatic tissue ablation via a single needle delivery system: Initial experience with radio-frequency energy and ethanol. Prostate Cancer Prostatic Dis. 2002;5(3):183-188.
  61. Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT). Transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia. Paris, France: CEDIT; 2000. 
  62. Medical Services Advisory Committee (MSAC). TransUrethral Needle Ablation (TUNA) for the treatment of benign prostatic hyperplasia. MSAC Application 1014. Canberra, ACT: MSAC; 2002.
  63. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol. 2002;19(6):426-435.
  64. Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044.
  65. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(3):CD001423.
  66. Eaton AC, Francis RN. The provision of transurethral prostatectomy on a day-case basis using bipolar plasma kinetic technology. BJU Int. 2002;89(6):534-537.
  67. National Institute for Clinical Excellence (NICE). KTP laser (60-80W) vaporisation of the prostate. Interventional Procedure Consultation Document. London, UK: NICE; June 2003. Available at: http://www.nice.org.uk/article.asp?a=91073. Accessed January 2004.
  68. Klingler HC. New innovative therapies for benign prostatic hyperplasia: Any advance? Curr Opin Urol. 2003;13(1):11-15.
  69. American Urologic Association (AUA), Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530-547.
  70. Tooher, RL, Scott A, Maddern G, et al. A systematic review of holmium laser prostatectomy. ASERNIP-S Report No.23. Adelaide, SA: Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP-S); June 2003.
  71. National Institute for Clinical Excellence (NICE). Transurethral electrovaporisation of the prostate.  Interventional Procedure Guidance 14. London, UK: NICE; October 2003. Available at: http://www.nice.org.uk/cms/htm/default/en/IP_112/ipg014guidance/docref.aspx. Accessed February 5, 2004.
  72. National Institute for Clinical Excellence (NICE). Transurethral radiofrequency needle ablation of the prostate. Interventional Procedure Guidance 15. London, UK: NICE; October 2003. Available at: http://www.nice.org.uk/cms/htm/default/en/IP_113/ipg015guidance/docref.aspx. Accessed February 5, 2004.
  73. Ogiste JS, Cooper K, Kaplan SA. Are stents still a useful therapy for benign prostatic hyperplasia? Curr Opin Urol. 2003;13(1):51-57.
  74. Corica AP, Larson BT, Sagaz A, et al. A novel temporary prostatic stent for the relief of prostatic urethral obstruction. BJU Int. 2004;93(3):346-348.
  75. Henderson A, Laing RW, Langley SE. A Spanner in the works: The use of a new temporary urethral stent to relieve bladder outflow obstruction after prostate brachytherapy. Brachytherapy. 2002;1(4):211-218.
  76. Isotalo T, Talja M, valimma T, et al. A bioabsorbable self-expandable, self-reinforced poly-L-lactic acid urethral stent for recurrent urethral strictures: Long-term results. J Endourol. 2002;16(10):759-762.
  77. Finnish Medical Society Duodecim. Benign prostatic hyperplasia. In: EBM Guidelines. Evidence-Based Medicine [CD-ROM]. Helsinki, Finland: Duodecim Medical Publications Ltd.; April 10, 2004.
  78. van Dijk MM, de la Rosette J. Prostatic stents in the treatment of benign prostatic hyperplasia.  Business Briefing: Global Surgery. 2003:1-6.
  79. Pizzoccaro M, Cantanzaro M, Stubinski R, et al. [The use of temporary stents in the treatment of urethral stenosis]. Arch Ital Urol Androl. 2002;74(3):111-112.
  80. Azuma H, Chancellor MB. Overview of biodegradable urethral stents. Rev Urol. 2004;6(2))98-99.
  81. Tammela TL, Talja M. Biodegradable urethral stents. BJU Int. 2003;92:843-850.
  82. AbbeyMoor Medical, Inc. The Spanner Prostatic Stent [website]. Miltona, MN: AbbeyMoor Medical; 2004. Available at: http://www.abbeymoormedical.com/. Accessed October 22, 2004.
  83. Hoffman RM, MacDonald R, Wilt TJ. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. 2000;(1):CD001987.
  84. California Technology Assessment Forum (CTAF). Water-induced thermotherapy for benign prostatic hyperplasia. San Francisco, CA: CTAF; February 13, 2002. Available at: http://ctaf.org/ass/viewfull.ctaf?id=6048341339. Accessed March 23, 2005.
  85. National Institute for Health and Clinical Excellence (NICE). Potassium-titanyl-phosphate (KTP) laser vaporisation of the prostate for benign prostatic obstruction. Interventional Procedure Guidance 120. London, UK: NICE; May 2005.
  86. Naspro R, Salonia A, Colombo R, et al. Update of the minimally invasive therapies for benign prostatic hyperplasia. Curr Opin Urol. 2005;15(1):49-53.
  87. Tan AH, Gilling PJ. Lasers in the treatment of benign prostatic hyperplasia: An update. Curr Opin Urol. 2005;15(1):55-58.
  88. Webber R. Benign prostatic hyperplasia. In: Clinical Evidence. London, UK: BMJ Publishg Group; May 2004.
  89. National Institute for Health and Clinical Excellence (NICE). Transurethral electrovaporisation of the prostate, guidance. Interventional Procedure Guidance 14. London, UK: NICE; October 2003. Available at: http://www.nice.org.uk/page.aspx?o=ipg014guidance. Accessed January 26, 2007.
  90. Nuhoglu B, Ayyildiz A, Fidan V, et al. Transurethral electrovaporization of the prostate: Is it any better than standard transurethral prostatectomy? 5-year follow-up. J Endourol. 2005;19(1):79-82.
  91. Fowler C, McAllister W, Plail R, et al. Randomsed evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. Health Tech Assess. 2005;9(4):iii-iv, 1-30. Available at: http://www.hta.ac.uk/execsumm/summ904.htm. Accessed January 26, 2007.
  92. Thomas CA, Chuang YC, Giannantoni A, Chancellor MB. Botulinum A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. Curr Urol Rep. 2006;7(4):266-271.
  93. Azzouzi AR, Fourmarier M, Desgrandchamps F, et al. Other therapies for BPH patients: Desmopressin, anti-cholinergic, anti-inflammatory drugs, and botulinum toxin. World J Urol. 2006;24(4):383-388.
  94. Chuang YC, Chancellor MB. The application of botulinum toxin in the prostate. J Urol. 2006;176(6 Pt 1):2375-2382.
  95. Armitage JN, Rashidian A, Cathcart PJ, et al. The thermo-expandable metallic stent for managing benign prostatic hyperplasia: A systematic review. BJU Int. 2006;98(4):806-810.
  96. Ontario Ministry of Health and Long-Term Care, Medical Advisory Secretariat (MAS).  Energy delivery systems for treatment of benign prostatic hyperplasia: Health Technology Policy Assessment. Toronto, ON: MAS; August 2006.
  97. Murtagh J, Foerster V. Photoselective vaporization for benign prostatic hyperplasia. Issues in Emerging Health Technologies Issue 95. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); 2006.
  98. Fried NM. New laser treatment approaches for benign prostatic hyperplasia. Curr Urol Rep. 2007;8(1):47-52.
  99. Daehlin L, Frugård J. Interstitial laser coagulation in the management of lower urinary tract symptoms suggestive of bladder outlet obstruction from benign prostatic hyperplasia: Long-term follow-up. BJU Int. 2007;100(1):89-93..
  100. Vanderbrink BA, Rastinehad AR, Badlani GH. Prostatic stents for the treatment of benign prostatic hyperplasia. Curr Opin Urol. 2007;17(1):1-6.
  101. Armitage JN, Cathcart PJ, Rashidian A, et al. Epithelializing stent for benign prostatic hyperplasia: A systematic review of the literature. J Urol. 2007;177(5):1619-1624.  
  102. Plante MK, Marks LS, Anderson R, et al. Phase I/II examination of transurethral ethanol ablation of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 2007;177(3):1030-1035; discussion 1035.
  103. Hoffman RM, Monga M, Elliot SP, et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2007;(4):CD004135.
  104. National Institute for Health and Clinical Excellence (NICE). Laparoscopic prostatectomy for benign prostatic obstruction. Interventional Procedure Guidance 275. London, UK: NICE; November 2008.
  105. Kaye JD, Smith AD, Badlani GH, et al. High-energy transurethral thermotherapy with CoreTherm approaches transurethral prostate resection in outcome efficacy: A meta-analysis. J Endourol. 2008;22(4):713-718.
  106. O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis. 2008;11(2):129-133.
  107. Lourenco T, Pickard R, Vale L, et al; Benign Prostatic Enlargement team. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: Systematic review of randomised controlled trials. BMJ. 2008;337:a449.
  108. Lourenco T, Armstrong N, N'Dow J, et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technol Assess. 2008;12(35):iii, ix-x, 1-146, 169-515.
  109. Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Non-drug local procedures in the treatment of benign prostatic hyperplasia. Executive Summary. IQWiG Reports - Commission No. N04-01. Cologne, Germany: IQWiG; 2008.
  110. Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Non-drug local procedures in the treatment of benign prostatic hyperplasia - update. Executive Summary. IQWiG Reports - Commission No. N09-01. Cologne, Germany: IQWiG; 2009.
  111. Paz-Valinas L. Photoselective vaporization for benign prostatic hyperplasia with KTP (potassium-titanyl-phosphate) laser or GreenLight [summary]. CT2007/04. Santiago de ComPostela. Spain: Galician Agency for Health Technology Assessment (AVALIA-T); December 2007.
  112. Paz-Valinas L, Atienza G. Holmium laser enucleation of benign prostatic hyperplasia [summary]. CT2009/01. Santiago de ComPostela, Spain: Galician Agency for Health Technology Assessment (AVALIA-T); March 2009.
  113. Ruszat R, Wyler SF, Seitz M, et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: Update of a prospective non-randomized two-centre study. BJU Int. 2008;102(10):1432-1438; discussion 1438-1439.
  114. Richter M, Schwarz J, De Geeter P, Albers P. Holmium laser ablation of the prostate. An alternative to GreenLight photoselective vaporization of the prostate. Urologe A. 2009;48(3):291-295.
  115. Erol A, Cam K, Tekin A, et al. High power diode laser vaporization of the prostate: Preliminary results for benign prostatic hyperplasia. J Urol. 2009;182(3):1078-1082.
  116. Van Cleynenbreugel B, Srirangam SJ, Van Poppel H. High-performance system GreenLight laser: Indications and outcomes. Curr Opin Urol. 2009;19(1):33-37.
  117. Naspro R, Bachmann A, Gilling P, et al. A review of the recent evidence (2006-2008) for 532-nm photoselective laser vaporisation and holmium laser enucleation of the prostate. Eur Urol. 2009;55(6):1345-1357.
  118. Chung DE, Te AE. New techniques for laser prostatectomy: An update. Therapeut Advances Urol. 2009;1(2):85-97.
  119. Elmansy HM, Elzayat E, Elhilali MM. Holmium laser ablation versus photoselective vaporization of prostate less than 60 cc: Long-term results of a randomized trial. J Urol. 2010;184(5):2023-2028.
  120. Oeconomou A, Madersbacher H. Botulinum neurotoxin A for benign prostatic hyperplasia. Curr Opin Urol. 2010;20(1):28-36.
  121. Hashim H, Abrams P. Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs. 2010;15(2):159-174.
  122. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol. 2010;20(1):49-54.
  123. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292-301.
  124. Food and Drug Administration. FDA approves Cialis to treat benign prostatic hyperplasia. October 6, 2011. FDA: Silver Spring, MD. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm274642.htm. Accessed January 12, 2012.
  125. Gravas S, Bachmann A, Reich O, et al. Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int. 2011;107(7):1030-1043.
  126. Herrmann TR, Liatsikos EN, Nagele U, et al; EAU Guidelines Panel on Lasers, Technologies. EAU guidelines on laser technologies. Eur Urol. 2012;61(4):783-795.
  127. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: Two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012;79(1):5-11.
  128. Barkin J, Giddens J, Incze P, et al. UroLift system for relief of prostate obstruction under local anesthesia. Can J Urol. 2012;19(2):6217-6222.
  129. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: The L.I.f.T. Study. J Urol. 2013;190(6):2161-2167.
  130. U.S. Food and Drug Administration (FDA). New medical device treats urinary symptoms related to enlarged prostate. FDA News. Silver Spring, MD: FDA; September 13, 2013. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm368325.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed November 13, 2013.
  131. Pisco JM, Pinheiro LC, Bilhim T, et al. Prostatic arterial embolization to treat benign prostatic hyperplasia. J Vasc Interv Radiol. 2011;22(1):11-19; quiz 20.
  132. Fernandes L, Rio Tinto H, Pereira J, et al. Prostatic arterial embolization: Post-procedural follow-up. Tech Vasc Interv Radiol. 2012;15(4):294-299.
  133. Pisco J, Campos Pinheiro L, Bilhim T, et al. Prostatic arterial embolization for benign prostatic hyperplasia: Short- and intermediate-term results. Radiology. 2013;266(2):668-677.
  134. McNicholas TA, Woo HH, Chin PT, et al. Minimally invasive prostatic urethral lift: Surgical technique and multinational experience. Eur Urol. 2013;64(2):292-299.
  135. McVary KT, Gange SN, Shore ND, et al; L.I.F.T. Study Investigators. Treatment of LUTS secondary to BPH while preserving sexual function: Randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11(1):279-287.
  136. National Institute for Health and Clinical Excellence (NICE). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. Interventional Procedure Guidance 475. London, UK: NICE; January 2014.


email this page   


Copyright Aetna Inc. All rights reserved. Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
Aetna
Back to top